Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.
暂无分享,去创建一个
[1] W. Fiers,et al. TUMOR NECROSIS FACTOR INCREASES THE PRODUCTION OF PLASMINOGEN ACTIVATOR INHIBITOR IN HUMAN ENDOTHELIAL CELLS IN VITRO AND IN RATS IN VIVO , 1988, Thrombosis and Haemostasis.
[2] B. Beutler,et al. CACHECTIN: MORE THAN A TUMOR NECROSIS FACTOR , 1988 .
[3] J. Adamson,et al. Disparate effects of tumor necrosis factor-alpha/cachectin and tumor necrosis factor-beta/lymphotoxin on hematopoietic growth factor production and neutrophil adhesion molecule expression by cultured human endothelial cells. , 1987, Journal of immunology.
[4] S. Moncada,et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.
[5] D. Remick,et al. Acute in vivo effects of human recombinant tumor necrosis factor. , 1987, Laboratory investigation; a journal of technical methods and pathology.
[6] W. Fiers,et al. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[7] R. Smith,et al. The active form of tumor necrosis factor is a trimer. , 1987, The Journal of biological chemistry.
[8] J. D. Albert,et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. , 1987, Surgery, gynecology & obstetrics.
[9] B. Aggarwal,et al. Receptor Binding and Activation of Polymorphonuclear Neutrophils by Tumor Necrosis Factor‐Alpha , 1987, Journal of leukocyte biology.
[10] A. Waage,et al. ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.
[11] A. Asher,et al. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. , 1987, Journal of immunology.
[12] Y. Kobayashi,et al. Production of lymphotoxin and tumour necrosis factor by a T-cell hybridoma. , 1987, Immunology.
[13] C. Nathan,et al. Secretory products of macrophages. , 1987, The Journal of clinical investigation.
[14] R. Pain,et al. Tumour necrosis factor is a compact trimer , 1987, FEBS letters.
[15] D. Loskutoff,et al. INTERLEUKIN 1 (IL-1) AND TUMOR NECROSIS FACTOR (TNF) ACTIVATION OF VASCULAR ENDOTHELIUM: EFFECTS ON PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) AND TISSUE-TYPE PLASMINOGEN ACTIVATOR (tPA) , 1987, Thrombosis and Haemostasis.
[16] A. Waage,et al. Detection of Tumour Necrosis Factor‐Like Cytotoxicity in Serum from Patients With Septicaemia but Not from Untreated Cancer Patients , 1986, Scandinavian journal of immunology.
[17] J. D. Albert,et al. Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.
[18] L. Old,et al. Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor , 1986, The Journal of experimental medicine.
[19] R. Philip,et al. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, γ-interferon and interleukin-1 , 1986, Nature.
[20] R. Ulevitch,et al. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum , 1986, The Journal of experimental medicine.
[21] G. Weissmann,et al. Tumor necrosis factor provokes superoxide anion generation from neutrophils. , 1986, Biochemical and biophysical research communications.
[22] H. Ochs,et al. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. , 1986, Journal of immunology.
[23] J. Gamble,et al. Stimulation of neutrophils by tumor necrosis factor. , 1986, Journal of immunology.
[24] W. Fiers,et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[25] B. Beutler,et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 , 1986, The Journal of experimental medicine.
[26] L. Chess,et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1 , 1986, The Journal of experimental medicine.
[27] J. Larrick,et al. Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. , 1986, Biochemical and biophysical research communications.
[28] S. Kuroda,et al. Molecular cloning and expression in Escherichia coli of the cDNA coding for rabbit tumor necrosis factor. , 1986, DNA.
[29] W. Fiers,et al. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. , 1986, The American journal of pathology.
[30] B. Beutler,et al. Cachectin and tumour necrosis factor as two sides of the same biological coin , 1986, Nature.
[31] C. Galanos,et al. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin , 1986, Infection and immunity.
[32] D. Stern,et al. Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.
[33] J. D. Albert,et al. Cachectin/tumor necrosis factor participates in reduction of skeletal muscle membrane potential: Evidence for bioactivity in plasma during critical illness , 1986 .
[34] Flick Da,et al. Pharmacokinetics of murine tumor necrosis factor. , 1986 .
[35] D. A. Flick,et al. Pharmacokinetics of murine tumor necrosis factor. , 1986, Journal of immunopharmacology.
[36] J. Gamble,et al. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[37] B. Aggarwal,et al. Human interleukin 1 is a cytocidal factor for several tumor cell lines. , 1985, Journal of immunology.
[38] B. Beutler,et al. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. , 1985, Journal of immunology.
[39] L. Old,et al. Tumor necrosis factor (TNF). , 1985, Science.
[40] A. Sakurai,et al. PURIFICATION AND PARTIAL AMINO ACID SEQUENCE OF RABBIT TUMOR NECROSIS FACTOR , 1985, International journal of cancer.
[41] B. Beutler,et al. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.
[42] B. Beutler,et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.
[43] B. Beutler,et al. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells , 1985, The Journal of experimental medicine.
[44] D. Goeddel,et al. Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.
[45] J. Quesada,et al. Pharmacokinetic study of partially pure gamma-interferon in cancer patients. , 1984, Cancer research.
[46] J A Koziol,et al. VARCOV: a computer program for the distribution-free analysis of growth and response curves. , 1984, Computer programs in biomedicine.
[47] R. Ulevitch,et al. Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s). , 1983, Journal of immunology.
[48] J. Oppenheim,et al. Antigen presentation by human monocytes: evidence for stimulant processing and requirement for interleukin 1. , 1983, Journal of immunology.
[49] G. Gifford,et al. In vitro production of rabbit macrophage tumor cell cytotoxin , 1983, International journal of cancer.
[50] S. Rosenberg,et al. The fate of interleukin-2 after in vivo administration. , 1983, Journal of immunology.
[51] J. Lipton,et al. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. , 1982, The Journal of clinical investigation.
[52] R. Munford,et al. Sites of tissue binding and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: studies in the rat and squirrel monkey. , 1981, The Journal of clinical investigation.
[53] T. Boulikas,et al. Silver staining of proteins in polyacrylamide gels. , 1981, Analytical biochemistry.
[54] R. Ulevitch,et al. In vivo interaction of bacterial lipopolysaccharide (LPS) with rabbit platelets: modulation by C3 and high density lipoproteins. , 1981, Journal of immunology.
[55] G. Gifford,et al. Purification and physico-chemical characterization of rabbit tumor necrosis factor. , 1980, Journal of immunology.
[56] C. Galanos,et al. Interaction of lipopolysaccharides with plasma high-density lipoprotein in rats. , 1980, Infection and immunity.
[57] R. Ulevitch,et al. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. , 1979, Journal of immunology.
[58] R. Ulevitch,et al. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides. , 1979, The Journal of clinical investigation.
[59] R. Ulevitch,et al. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. , 1978, The Journal of clinical investigation.
[60] R. Ulevitch,et al. The effects of bacterial endotoxins on host mediation systems. A review. , 1978, The American journal of pathology.
[61] R. Ulevitch,et al. The effect of complement depletion on bacterial lipopolysaccharide (LPS)-induced hemodynamic and hematologic changes in the Rhesus monkey. , 1978, The American journal of pathology.
[62] P. Fraker,et al. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.
[63] R. Ulevitch,et al. Role of complement in lethal bacterial lipopolysaccharide-induced hypotensive and coagulative changes , 1978, Infection and immunity.
[64] D. Rosenstreich,et al. Significant contribution of spleen cells in mediating the lethal effects of endotoxin in vivo , 1976, Infection and immunity.
[65] R. Ulevitch,et al. Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement , 1975, The Journal of experimental medicine.
[66] O. Westphal. Bacterial Endotoxins (Part 2 of 2) , 1975 .
[67] C. Shipman. Trypsin: A. Mammalian Tissues , 1973 .
[68] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[69] C. Galanos,et al. A new method for the extraction of R lipopolysaccharides. , 1969, European journal of biochemistry.
[70] R. Aster,et al. PLATELET SEQUESTRATION IN MAN. I. METHODS. , 1964, The Journal of clinical investigation.
[71] G. Ashwell,et al. Estimation of 3-Deoxy Sugars by Means of the Malonaldehyde–Thiobarbituric Acid Reaction , 1960, Nature.